Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Merck and Pfizer are to take on the crowded SGLT2 ... day at list price. The US approval has achieved, the companies await similar clearance in Europe, the other leading market for the drugs.

"If we want to maximize the benefits of SGLT2 [inhibitors], we need to start patients on them early, keep them on them, and not stop the drug," Herrington said at the late-breaking session.

2023 Diabetes Drug Class Appears to Reduce Recurrent Gout Flares Previously associated with a lower incidence of gout, sodium-glucose cotransporter-2 (SGLT2) inhibitors for the first time also ...

The FDA is expected to decide on treatments for familial chylomicronemia syndrome, type 1 diabetes, short bowel syndrome, and Prader-Willi syndrome.

Because this list isn't complete ... If you have type 2 diabetes, you can choose a similar SGLT2 inhibitor to Jardiance, such as Invokana (canagliflozin). Because both drugs stop a protein that ...

Dr. Nir Barzilai, the director of the Institute for Aging Research at the Albert Einstein College of Medicine and scientific director at The American Federation for Aging Research (AFAR), predicts it ...